Literature DB >> 24744983

O-GlcNAc cycling shows neuroprotective potential in C. elegans models of neurodegenerative disease.

John A Hanover1, Peng Wang1.   

Abstract

C. elegans has proven to be an excellent organism in which to model human neurodegenerative disease.(1) (-) (7) The worm's simple nervous system, lineage, and neural maps, easily scored movement phenotypes, and robust forward and reverse genetics make it optimal for studying age-dependent processes on a reasonable time scale. A popular approach has been the introduction of transgenes expressing GFP-tagged proteotoxic human proteins into neurons leading to visible aggregation or movement phenotypes.(2) (,) (4) (,) (6) (,) (8) (-) (13) In addition, the maintenance of proteostasis networks has been extensively studied using the power of worm genetics.(8) (-) (13) These networks include genes involved in insulin-like signaling, the heat shock response, the response to hypoxia, and mTOR and AMPK pathways linked to aging.(14) Another pathway with suggestive links to neurodegeneration is the O-GlcNAc cycling pathway, a nutrient-dependent post-translational modification known to be altered in brains from patients with Alzheimer disease.(15) (-) (19) In this commentary, we summarize our recent findings showing that viable mutants of O-GlcNAc cycling in C. elegans dramatically alter the neurotoxicity of four distinct C. elegans models of neurodegenerative disease.(7) Mutants in O-GlcNAc cycling alter the toxicity of mutant tau, polyglutamine expansion reporters, and amyloid β-peptide. The findings further suggest that O-GlcNAc cycling acts at many steps in the lifecycle of aggregation-prone targets. The C. elegans system is likely to continue to provide insights into this complex problem. The involvement of O-GlcNAc cycling in the maintenance of proteostasis raises the possibility of targeting the enzymes catalyzing this critical post-translational modification for therapeutic intervention.

Entities:  

Keywords:  O-GlcNAc; apoptosis; glycobiology; neurodegeneration; proteostasis; signaling; transcription

Year:  2013        PMID: 24744983      PMCID: PMC3917942          DOI: 10.4161/worm.27043

Source DB:  PubMed          Journal:  Worm        ISSN: 2162-4046


  45 in total

Review 1.  A predictable worm: application of Caenorhabditis elegans for mechanistic investigation of movement disorders.

Authors:  Paige M Dexter; Kim A Caldwell; Guy A Caldwell
Journal:  Neurotherapeutics       Date:  2012-04       Impact factor: 7.620

2.  Conversion of green fluorescent protein into a toxic, aggregation-prone protein by C-terminal addition of a short peptide.

Authors:  Christopher D Link; Virginia Fonte; Brian Hiester; John Yerg; Jmil Ferguson; Susan Csontos; Michael A Silverman; Gretchen H Stein
Journal:  J Biol Chem       Date:  2005-10-19       Impact factor: 5.157

Review 3.  Watching worms whither: modeling neurodegeneration in C. elegans.

Authors:  Benjamin Wolozin; Christopher Gabel; Andrew Ferree; Maria Guillily; Atsushi Ebata
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

4.  Potential neuroprotective strategies against tauopathy.

Authors:  Jeanna M Wheeler; Chris R Guthrie; Brian C Kraemer
Journal:  Biochem Soc Trans       Date:  2012-08       Impact factor: 5.407

5.  Caenorhabditis elegans ortholog of a diabetes susceptibility locus: oga-1 (O-GlcNAcase) knockout impacts O-GlcNAc cycling, metabolism, and dauer.

Authors:  Michele E Forsythe; Dona C Love; Brooke D Lazarus; Eun Ju Kim; William A Prinz; Gilbert Ashwell; Michael W Krause; John A Hanover
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-01       Impact factor: 11.205

Review 6.  Caenorhabditis elegans as a model system to study intercompartmental proteostasis: Interrelation of mitochondrial function, longevity, and neurodegenerative diseases.

Authors:  Janine Kirstein-Miles; Richard I Morimoto
Journal:  Dev Dyn       Date:  2010-05       Impact factor: 3.780

7.  Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging.

Authors:  Anat Ben-Zvi; Elizabeth A Miller; Richard I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

8.  Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy.

Authors:  Brian C Kraemer; Bin Zhang; James B Leverenz; James H Thomas; John Q Trojanowski; Gerard D Schellenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-18       Impact factor: 11.205

9.  Elevated O-GlcNAc-dependent signaling through inducible mOGT expression selectively triggers apoptosis.

Authors:  Sang-Hoon Shin; Dona C Love; John A Hanover
Journal:  Amino Acids       Date:  2010-09-08       Impact factor: 3.520

10.  Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation.

Authors:  Yang Yu; Lan Zhang; Xiaojing Li; Xiaoqin Run; Zhihou Liang; Yi Li; Ying Liu; Moon H Lee; Inge Grundke-Iqbal; Khalid Iqbal; David J Vocadlo; Fei Liu; Cheng-Xin Gong
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

View more
  13 in total

Review 1.  Multiple tissue-specific roles for the O-GlcNAc post-translational modification in the induction of and complications arising from type II diabetes.

Authors:  Krithika Vaidyanathan; Lance Wells
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

Review 2.  Nutrient-driven O-GlcNAc in proteostasis and neurodegeneration.

Authors:  Ilhan Akan; Stephanie Olivier-Van Stichelen; Michelle R Bond; John A Hanover
Journal:  J Neurochem       Date:  2017-11-20       Impact factor: 5.372

3.  Conditional knock-out reveals a requirement for O-linked N-Acetylglucosaminase (O-GlcNAcase) in metabolic homeostasis.

Authors:  Chithra Keembiyehetty; Dona C Love; Katryn R Harwood; Oksana Gavrilova; Marcella E Comly; John A Hanover
Journal:  J Biol Chem       Date:  2015-01-16       Impact factor: 5.157

4.  Loss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration.

Authors:  Andrew C Wang; Elizabeth H Jensen; Jessica E Rexach; Harry V Vinters; Linda C Hsieh-Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-12       Impact factor: 11.205

5.  Gigaxonin glycosylation regulates intermediate filament turnover and may impact giant axonal neuropathy etiology or treatment

Authors:  Po-Han Chen; Jimin Hu; Jianli Wu; Duc T Huynh; Timothy J Smith; Samuel Pan; Brittany J Bisnett; Alexander B Smith; Annie Lu; Brett M Condon; Jen-Tsan Chi; Michael Boyce
Journal:  JCI Insight       Date:  2019-11-26

Review 6.  Tau physiology and pathomechanisms in frontotemporal lobar degeneration.

Authors:  Liviu-Gabriel Bodea; Anne Eckert; Lars Matthias Ittner; Olivier Piguet; Jürgen Götz
Journal:  J Neurochem       Date:  2016-06-15       Impact factor: 5.372

Review 7.  The struggle by Caenorhabditis elegans to maintain proteostasis during aging and disease.

Authors:  Elise A Kikis
Journal:  Biol Direct       Date:  2016-11-03       Impact factor: 4.540

Review 8.  Alzheimer's Disease and Type 2 Diabetes: A Critical Assessment of the Shared Pathological Traits.

Authors:  Shreyasi Chatterjee; Amritpal Mudher
Journal:  Front Neurosci       Date:  2018-06-08       Impact factor: 4.677

9.  Evidence for nutrient-dependent regulation of the COPII coat by O-GlcNAcylation.

Authors:  Brittany J Bisnett; Brett M Condon; Noah A Linhart; Caitlin H Lamb; Duc T Huynh; Jingyi Bai; Timothy J Smith; Jimin Hu; George R Georgiou; Michael Boyce
Journal:  Glycobiology       Date:  2021-09-20       Impact factor: 5.954

10.  Modulation of O-GlcNAcylation Regulates Autophagy in Cortical Astrocytes.

Authors:  Md Ataur Rahman; Hongik Hwang; Yoonjeong Cho; Hyewhon Rhim
Journal:  Oxid Med Cell Longev       Date:  2019-11-13       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.